Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IONC301
- Development stage
- Unknown
- Lead developer
- iOncologi
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
IONC301 is an autologous immunomodulatory cell-based therapy being developed by iOncologi for the treatment of pediatric glioblastoma (GBM). The therapy consists of patient-derived hematopoietic stem cells (HSCs) enriched for CD34 and lineage-negative (Lin-) markers, along with an additional undisclosed marker. IONC301 is designed to induce a systemic immune "reboot" and reprogram the immune environment to modulate anti-tumor immunity. Preclinical evidence suggests that this approach can enhance responsiveness to PD-1 checkpoint inhibitors in resistant glioblastoma models. The candidate is currently undergoing Phase 1 clinical evaluation in pediatric patients.
Beyond the preview
Go deeper on IONC301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IONC301.